

Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Shima Balali-Dehkordi¹

¹ Shahrekord University

Potential competing interests: No potential competing interests to declare.

Dear Editor,

On manuscript entitled " Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"

Comments:

1- Text should be edited. There are various typo and grammatical errors.

2- Abstract need to rewrite, methods and results should be added in brief and clear way.

3- introduction is too long. You should concise the introduction. in the current form, AD explained more. I suggest that introduction write in 4 separate paragraph (1-AD and its complications, pathophysiology and ...2- Role of nrf2, neuroinflammation and oxidative stress and ... in the pathophysiology of AD, 3- Isoeugenol and its pharmacological and pharmacokinetic effects and 4- aim of study)

4-Results should be deleted from end of introduction section.

5-all methods need appropriate references.

6-How many mice were used?

7- What is your rational for dose and time of agent administrations?

8- Why number of mice in groups is different?

9- A schematic for study design in mice is needed to help better understanding.

10- methods used for sacrificing are different for Pharmacokinetic and pharmacodynamic studies. Please clarify. Doses of ketamine and xylazine need references

11- gene expressions were measured in which samples? please clarify.

12-rational for performing hot plate test should be clarified.

13- did each mouse subjected to one trial? if not, please clarify timeline with

intervals between tests.

14- If possible please concise methods. primers include in table.

15-please show histopathological changes in figure.

16-Discussion is too long with unnecessary topic in some points. strongly suggested that brief this section. limitation of study should be added.